[Pharmacologic treatment of bronchial cancer. Part 1: Standards].
In the last decade there have been important innovations in the treatment of lung tumors. New combined modality therapies are becoming standard and require a network of cooperating partners. New therapeutic agents are under investigation that will hopefully improve the outcome of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Principles of chemotherapy in non-small cell und small cell lung cancer depending on stage and combination in multimodal regimens are shown. In the second part single drugs are described with their typical effects and side effects from the viewpoint of a clinician. A following part II will discuss new "targeted" biologicals.
Serke
M
M
Zentrum für Pneumologie und Thoraxchirurgie, Heckeshorn, Helios-Klinikum Emil-von-Behring, Berlin. m.serke@behring.helios-kliniken.de
D000970:Antineoplastic Agents / Q000592:standards* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011785:Quality Assurance, Health Care
D000970:Antineoplastic Agents